BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ResMed Inc. (RMD) To Acquire Saime SA


10/19/2005 5:10:27 PM

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ResMed Inc today announced that it has entered into a definitive agreement to acquire Saime SA, a leading developer and distributor of ventilation products in France and Germany. ResMed has agreed to acquire Financiere ACE SAS, the holding company for Saime SA and its affiliates, for an enterprise value of approximately 86 million Euro, consisting of approximately 40 million Euro in equity and approximately 46 million Euro in net debt. ResMed expects to finance the acquisition with a combination of existing cash reserves and debt. ResMed expects the acquisition will close in May 2005, with an insignificant impact on earnings for fiscal year 2005.

"The acquisition of Saime will complete our line of homecare ventilation products and immediately expand our market presence and distribution network in Europe and other regions," stated Peter C. Farrell, PhD, ResMed's Chairman and Chief Executive Officer. "The VS and Elisee range of products are sophisticated, yet easy to use for physicians, clinicians, and patients. We believe these devices will complement our VPAP III and AutoSet CS devices and will allow us to provide the full range of options for patients who need ventilatory assistance."

"We are proud of Saime's history of revenue and profit growth and of our commitment to developing high-quality, differentiated products," said Antoine Heral, Chief Executive Officer of Saime. "ResMed's strength and reputation as a quality leader with worldwide distribution and innovative technologies make them an excellent match for Saime."

ResMed and Saime have had a long-standing relationship since 1996, when ResMed bought its original French sleep therapy distribution assets from the Saime group. Since its formation in 1987, Saime has developed a complete range of ventilators for use in the home and hospital markets. With annual revenues of approximately 28 million Euro, the company distributes its products directly in France and Germany and through a network of distributors in Europe and Asia-Pacific. Today, Saime develops, manufactures, and markets products from its headquarters near Paris, with a staff of approximately 100.

About ResMed

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit http://www.resmed.com/.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the completion of the transaction, impact on earnings, benefits the products and technologies will provide, and the integration of the product line and operations, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the US Securities & Exchange Commission. Those reports are available on the Company's website.

ResMed Inc

CONTACT: Hillary Theakston, Director of Investor Relations of ResMedInc, +1-858-746-2610



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES